Giant-Cell Tumor of Tendon Sheath clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
open to eligible people ages 18 years and up
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.